Ocuphire Pharma Investor Presentation Deck

Preclinical Data: Oral APX3330 Blocks Neovascularization Lesion Volume Decrease with Oral APX3330 in Murine Laser CNV Model Similar to EYLEAⓇ Data L-CNV Mouse Retina Model Lesion Size and Corresponding Fluorescent Stains in L-CNV Models Treated with APX3330 at 25 mg/kg oral gavage APX3330 Vehicle Silva et al, 2021 Ocuphire 25 mg/kg 50 mg/kg Lesion Volume (µm³) APX3330 Gavage OCT Lesion Volume 8x106- 6x106 4x106- 2x106- 0 **** *** -55%. Vehicle 25 50 [APX3330] (mg/kg) (a) Day 7 (c) Silva et al. ARVO 2021 Annual Meeting *Published data on EYLEA. This study was performed independently from APX3330 study and is a cross-study comparison. **Li 2014; *** Pasha 2018; **** Jiang 2011 (Vldlr : Very Low-Density Lipoprotein receptor knock-out mice) Day 14 ONL L-CNV Mouse Retina Model *EYLEA Anti-VEGF164 Vehicle CNV lesion volume (μm³) 1.2x107- 9.0x106- 6.0x106- 3.0x106- 0.0- ✓ Efficacy was also seen after single intravitreal injection of 20μM APX3330 in mouse L-CNV model** ✓ Efficacy was also seen after dosing intraperitoneal injection of 50 mg/kg twice daily, 5 days on/2 days off, for 2 weeks in mouse L-CNV model*** ✓ Efficacy was also seen after single intravitreal injection of 20μM APX3330 in Vldlr/-mice model**** -44% Vehicle Anti-VEGF164 37

View entire presentation